Our results are in accordance with a prior report on co-administration of MIP-3beta gene with a beta-gal expressing plasmid indicating that co-administered formulation enhanced both theTh1 polarized cell-mediated and humoral immune responses as well as specific CD8+ T cells activities in a tumor cell-challenge vaccine study (16). Here, CD8A is linked to neoplasm.